Skip to main content
. 2022 Mar 4;107(6):1529–1540. doi: 10.1210/clinem/dgac117

Figure 5.

Figure 5.

Effects of kisspeptin on osteoclast activity. Kisspeptin dose-dependently decreased osteoclast activity in osteoclast monocultures (A-C), and osteoclast/osteoblast cocultures (D-F). (A, D) Changes in percentage eroded surface per bone surface from different osteoclast donors, as mean ± SEM (n = 8). (B, E) Effects of kisspeptin on osteoclast activity from each experiment connected with a line. Each dot represents the mean of 6 technical replicates per donor (B, n = 8; E, n = 8 [osteoclast donors], n = 8 [osteoblast donors]). (C, F) Percentage change in osteoclast activity compared with control with each dot representing the mean of 6 technical replicates per donor normalized to control (n as for B, E). A (**P = .0019), D (**P = .0052), repeated measures 1-way ANOVA and Dunnett’s multiple comparisons test. C (****P < .0001), F (0 vs 10 nM, 53.4% suppression, ****P < .0001), repeated measures 1-way ANOVA.